Immune Thrombocytopenic Purpura
Conditions
Keywords
Refractory Immune Thrombocytopenic Purpura, rapamycin, regulatory T cells
Brief summary
The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune Thrombocytopenic Purpura (RITP) and explore the further mechanism.
Detailed description
Rapamycin, an immunosuppressive drug, is widely used to prevent allograft rejection and autoimmune diseases. Many studies have shown that the drug contributes to the expansion of regulatory T cells and preserves the highly suppressive function of autoreactive T cells. Patients with RITP often display a decreased proportion of regulatory T cells by flow cytometer, therefore, the investigators will examine the efficacy of rapamycin in RITP patients.
Interventions
DRUGrapamycin
4mg oral administration on the first day, 2 mg/d oral administration for 3 months
Sponsors
First Affiliated Hospital of Suzhou Medical College
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Clinical diagnoses of idiopathic thrombocytopenic purpura * Hormone and immune suppression, splenectomy is invalid
Exclusion criteria
* patients had a bad tolerance to rapamycin * platelet counts \< 10\*10E9/L during the treatment of rapamycin
Countries
China
Outcome results
None listed